The authors declare that they have no competing interests.
DMY and QMZ conceived the study, analyzed data and wrote the manuscript. CJL and JYZ acquired and analyzed data, and wrote the manuscript. All authors read and approved the final manuscript.
To observe the efficacy and safety of adding glimepiride to established insulin therapy in poorly controlled type 2 diabetes (T2D) and to assess the relationship of changes in the serum high-molecular weight (HMW) adiponectin levels and glycemic control after glimepiride treatment.
Fifty-six subjects with poorly controlled insulin-treated T2D were randomly assigned to either the glimepiride-added group (the group A, n = 29) or the insulin-increasing group (the group B, n = 27) while continuing current insulin-based therapy. Glycosylated hemoglobin (HbA1c) value, daily insulin dose, body weight, waist circumference, plasma lipid concentration, serum HMW adiponectin level and the number of hypoglycemic events were evaluated before and after treatment.
At the end of study, insulin doses were significantly reduced, and the mean HbA1c, fasting blood glucose (FBG) and 2-hour postprandial blood glucose (P2BG) were improved greater in the group A compared with the group B. The serum HMW adiponectin levels were significantly increased in the group A compared with the group B. Most importantly, we found that changes in HbA1c were inversely correlated with changes in serum HMW adiponectin in the group A (r = −0.452, p = 0.02).
Adding glimepiride to current insulin treatment led to better improvement in glycemic control with a significant smaller daily insulin dose, and the increases in the serum HMW adiponectin levels may directly contribute to improvement glycemic control.
Heller S: Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diab Res Clin Pract. 2004, 65S: S23-S27. CrossRef
United Kingdom Prospective Diabetes Study: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. CrossRef
Lincoff AM Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007, 12; 298: 1180-1188. CrossRef
van Dieren S1, Czernichow S, Chalmers J, Kengne AP, de Galan BE, Poulter N, Woodward M, Beulens JW, Grobbee DE, van der Schouw YT, Zoungas S: Weight changes and their predictors amongst 11140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab. 2012, 14 (5): 464-469. 10.1111/j.1463-1326.2012.01556.x. CrossRefPubMed
Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S, Awata T, Katayama S: Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2005, 328 (2): 484-490. 10.1016/j.bbrc.2004.12.190. CrossRefPubMed
Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T: Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003, 278 (41): 40352-40363. 10.1074/jbc.M300365200. CrossRefPubMed
Kanda Y, Matsuda M, Tawaramoto K, Kawasaki F, Hashiramoto M, Matsuki M, Kaku K: Effects of sulfonylurea drugs on adiponectin production from 3 T3-L1 adipocytes: implication of different mechanism from pioglitazone. Diabetes Res Clin Pract. 2008, 81 (1): 13-18. 10.1016/j.diabres.2008.01.031. CrossRefPubMed
Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, Nomura N, Miyazaki A, Iguchi A: Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care. 2003, 26: 285-289. 10.2337/diacare.26.2.285. CrossRefPubMed
Liu M, Liu F: Regulation of adiponectin multimerization, signaling and function. J Clin Invest. 2006, 116 (7): 1784-1792. 10.1172/JCI29126. CrossRef
Aso Y, Hara K, Ozeki N, Yatsuka C, Nakano T, Matsumoto S, Suetsugu M, Nakamachi T, Takebayashi K, Haruki K, Inukai T: Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2009, 85 (2): 147-152. 10.1016/j.diabres.2009.05.015. CrossRefPubMed
Aso Y, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Matsutomo R, Takebayashi K, Inukai T: Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes. Diabet Med. 2007, 24 (9): 962-968. 10.1111/j.1464-5491.2007.02204.x. CrossRefPubMed
Ose H1, Fukui M, Kitagawa Y, Hirata C, Ichio N, Kadono M, Mogami S, Onishi M, Ichida Y, Nakajima T, Hasegawa G, Yoshikawa T, Nakamura N: Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus. Endocr J. 2005, 52: 563-569. 10.1507/endocrj.52.563. CrossRefPubMed
Johnson JL, Wolf SL, Kabadi UM: Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996, 12; 156 (3): 259-264. CrossRef
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS: The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010, 33 (6): 1224-1229. 10.2337/dc10-0017. PubMedCentralCrossRefPubMed
Okauchi Y, Kishida K, Funahashi T, Noguchi M, Ogawa T, Ryo M, Okita K, Iwahashi H, Imagawa A, Nakamura T, Matsuzawa Y, Shimomura I: Changes in serum adiponectin concentrations correlate with changes in BMI, waist circumference, and estimated visceral fat area in middle-aged general population. Diabetes Care. 2009, 32: e122-10.2337/dc09-1130. CrossRefPubMed
Nagasaka S, Taniguchi A, Aiso Y, Yatagai T, Nakamura T, Nakai Y: Glimepiride and serum adiponectin level in type 2 diabetic subjects. Diabetes Care. 2003, 26: 3361-10.2337/diacare.26.12.3361. CrossRef
- Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II